Piperidinyl prostaglandin E analogs

A compound represented by the general formula I;

• wherein hatched lines represent the α configuration, a triangle represents the β configuration, a wavy line represents either the α configuration or the β configuration and a dotted line represents the presence or absence of a double bond;
• D represents a covalent bond or CH2, O, S or NH;
• X is CO2R, CONR2, CH2OR, P(O)(OR)2, CONRSO2R, SONR2 or
• Z is CH2 or a covalent bond;
• R is H or R2;
• R1 is H, R2, phenyl, or COR2;
• R2 is C1-C5 lower alkyl or alkenyl and R3 is selected from the group consisting of R2, phenyl, thienyl, furanyl, pyridyl, benzothienyl, benzofuranyl, naphthyl, or substituted derivatives thereof, wherein the substituents maybe selected from the group consisting of C1-C5 alkyl, halogen, CF3, CN, NO2, NR2, CO2R and OR.

An ophthalmic solution comprising a therapeutically effective amount of a compound represented by the general Formula 1

• wherein hatched lines represent the α configuration, a triangle represents the β configuration, a wavy line represents the α configuration or the β configuration and a dotted line represents the presence or absence of a double bond;
• D represents a covalent bond or CH2, O, S or NH;
• X is C
• O2R, CONR2, CH2OR, P(O)(OR)2, CONRSO2R SONR2 or
• Z is CH2 or a covalent bond;
• R is H or R2;
• R1 is H, R2, phenyl, or COR2;
• R2 is C1-C5 lower alkyl or alkenyl and R3 is selected from the group consisting of R2, phenyl, thienyl, furanyl, pyridyl, benzothienyl, benzofuranyl, naphthyl or substituted derivatives thereof, wherein the substituents maybe selected from the group consisting of C1-C5 alkyl, halogen, CF3, CN, NO2, NR2, CO2R and OR in admixture with a non-toxic, ophthalmically acceptable liquid vehicle, packaged in a container suitable for metered application.